skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer

Abstract

Purpose: Intensity-modulated radiation therapy (IMRT) enables highly conformal treatment for thyroid cancer (TC). In this study, we review outcomes/toxicity in a series of TC patients treated with IMRT. Methods and Materials: Between July 2001 and January 2004, 20 nonanaplastic TC patients underwent IMRT. Mean age was 55. There were 3 T2 and 17 T4 patients. Sixteen patients had N1 disease. Seven patients had metastases before RT. Fifteen underwent surgery before RT. Radioactive iodine (RAI) and chemotherapy were used in 70% and 40%, respectively. Median total RT dose was 63 Gy. Results: With two local failures, 2-year local progression-free rate was 85%. There were six deaths, with a 2-year overall survival rate of 60%. For patients with M0 disease, the 2-year distant metastases-free rate was 46%. The worst acute mucositis and pharyngitis was Grade 3 (n = 7 and 3, respectively). Two patients had Grade 3 acute skin toxicity and 2 had Grade 3 acute laryngeal toxicity. No significant radiation-related late effects were reported. Conclusions: IMRT for TC is feasible and effective in appropriately selected cases. Acute toxicity is manageable with proactive clinical care. Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are neededmore » to confirm these preliminary findings and to clarify late toxicities.« less

Authors:
 [1];  [1];  [2];  [3];  [4];  [1];  [1];  [1];  [1];  [5]
  1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
  2. Department of Radiation Physics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
  3. Department of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
  4. Department of Endocrinology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
  5. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States). E-mail: leen2@mskcc.org
Publication Date:
OSTI Identifier:
20788234
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 63; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2005.05.043; PII: S0360-3016(05)00953-3; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; DEATH; FAILURES; IODINE ISOTOPES; METASTASES; NEOPLASMS; PATIENTS; PLANNING; RADIATION DOSES; RADIOTHERAPY; REVIEWS; SKIN; SURGERY; THYROID; TOXICITY

Citation Formats

Rosenbluth, Benjamin D., Serrano, Victoria B.S., Happersett, Laura, Shaha, Ashok R., Tuttle, R. Michael, Narayana, Ashwatha, Wolden, Suzanne L., Rosenzweig, Kenneth E., Chong, Lanceford M., and Lee, Nancy Y.. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. United States: N. p., 2005. Web. doi:10.1016/J.IJROBP.2005.0.
Rosenbluth, Benjamin D., Serrano, Victoria B.S., Happersett, Laura, Shaha, Ashok R., Tuttle, R. Michael, Narayana, Ashwatha, Wolden, Suzanne L., Rosenzweig, Kenneth E., Chong, Lanceford M., & Lee, Nancy Y.. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. United States. doi:10.1016/J.IJROBP.2005.0.
Rosenbluth, Benjamin D., Serrano, Victoria B.S., Happersett, Laura, Shaha, Ashok R., Tuttle, R. Michael, Narayana, Ashwatha, Wolden, Suzanne L., Rosenzweig, Kenneth E., Chong, Lanceford M., and Lee, Nancy Y.. Thu . "Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer". United States. doi:10.1016/J.IJROBP.2005.0.
@article{osti_20788234,
title = {Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer},
author = {Rosenbluth, Benjamin D. and Serrano, Victoria B.S. and Happersett, Laura and Shaha, Ashok R. and Tuttle, R. Michael and Narayana, Ashwatha and Wolden, Suzanne L. and Rosenzweig, Kenneth E. and Chong, Lanceford M. and Lee, Nancy Y.},
abstractNote = {Purpose: Intensity-modulated radiation therapy (IMRT) enables highly conformal treatment for thyroid cancer (TC). In this study, we review outcomes/toxicity in a series of TC patients treated with IMRT. Methods and Materials: Between July 2001 and January 2004, 20 nonanaplastic TC patients underwent IMRT. Mean age was 55. There were 3 T2 and 17 T4 patients. Sixteen patients had N1 disease. Seven patients had metastases before RT. Fifteen underwent surgery before RT. Radioactive iodine (RAI) and chemotherapy were used in 70% and 40%, respectively. Median total RT dose was 63 Gy. Results: With two local failures, 2-year local progression-free rate was 85%. There were six deaths, with a 2-year overall survival rate of 60%. For patients with M0 disease, the 2-year distant metastases-free rate was 46%. The worst acute mucositis and pharyngitis was Grade 3 (n = 7 and 3, respectively). Two patients had Grade 3 acute skin toxicity and 2 had Grade 3 acute laryngeal toxicity. No significant radiation-related late effects were reported. Conclusions: IMRT for TC is feasible and effective in appropriately selected cases. Acute toxicity is manageable with proactive clinical care. Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are needed to confirm these preliminary findings and to clarify late toxicities.},
doi = {10.1016/J.IJROBP.2005.0},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 5,
volume = 63,
place = {United States},
year = {Thu Dec 01 00:00:00 EST 2005},
month = {Thu Dec 01 00:00:00 EST 2005}
}